Last reviewed · How we verify
D-Ribose Powder
At a glance
| Generic name | D-Ribose Powder |
|---|---|
| Also known as | ribose |
| Sponsor | RiboCor, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants (PHASE2)
- The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors (PHASE1)
- CoQ10 and D-ribose in Patients With Diastolic Heart Failure (PHASE2)
- RibOSE - Glucose and Resistance Exercise Training (NA)
- Creatine, D-Ribose, B1 Vitamin, and B6 Vitamin in Ischemic Heart Disease (NA)
- Study To Evaluate D-Ribose For The Treatment of Congestive Heart Failure (PHASE2)
- D-Ribose for Fatigue in Subjects With Fibromyalgia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- D-Ribose Powder CI brief — competitive landscape report
- D-Ribose Powder updates RSS · CI watch RSS
- RiboCor, Inc. portfolio CI